News Center
News Type
Single-Dose Treatment! China’s First Novel Antiviral Influenza Drug Yisuda® Approved for Market
On March 27, 2025, Kvvit Pharmaceuticals, a subsidiary of Qingfeng Pharmaceutical Group, received approval to market Yisuda® Suraxavir Marboxil Tablets.
First Domestic Approval! Qingfeng Pharmaceutical’s Vancomycin Hydrochloride for Oral Solution Officially Approved for Market
On March 11, Qingfeng Pharmaceutical’s subsidiary, Corey Pharmaceuticals, received official approval from China’s National Medical Products Administration (NMPA) for its oral vancomycin hydrochloride solution, becoming the first company in China to obtain authorization for this product.
First Domestic Approval! Qingfeng Receives NMPA Approval for First Generic Pirampanel Oral Suspension
On March 21, Qingfeng Pharmaceutical’s subsidiary, Kvvit Pharmaceuticals, obtained NMPA approval to market the first domestically developed generic piracetam oral suspension.
Qingfeng and Kexing Biopharm Join Forces for Global Enzalutamide Launch
On January 16, Qingfeng Pharmaceutical Group’s subsidiary, Corey Pharmaceuticals, and Kexing Biopharm (688136.SH) officially signed an agreement to work together on the international promotion of Enzalutamide soft capsules.
The Phase III Clinical Study of China’s First Novel Anti-Infection Drug, Masorasavir Tablets, Published in Prestigious International Journal
On January 7, 2025, the Phase III clinical trial results for Suraxavir Marboxil Tablets, a Class 1 innovative drug developed by Qingfeng Pharmaceutical, were published in Nature Medicine (Impact Factor: 58.7).
Qingfeng will attend the 2025 J.P. Morgan Healthcare Conference
Qingfeng Pharmaceutical Group, will attend “The 43rd Annual J.P. Morgan Healthcare Conference” in San Francisco, from January 13-16, 2025.
